ATOS Key Statistics, Chart & Performance
The current stock price of ATOS is 0.7001 USD. In the past month the price decreased by -18.59%. In the past year, price decreased by -42.61%.
ATOS Latest News, Press Relases and Analysis
ATOS Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 23.74 | 396.55B | ||
| AMGN | AMGEN INC | 15.47 | 182.20B | ||
| GILD | GILEAD SCIENCES INC | 15.13 | 153.73B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 24.95 | 109.90B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.49 | 77.98B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 911.63 | 61.42B | ||
| INSM | INSMED INC | N/A | 44.06B | ||
| NTRA | NATERA INC | N/A | 32.66B | ||
| BIIB | BIOGEN INC | 10.76 | 26.43B | ||
| UTHR | UNITED THERAPEUTICS CORP | 17.97 | 20.42B | ||
| INCY | INCYTE CORP | 15.8 | 19.91B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.20B |
Related stock screener links
About ATOS
Company Profile
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
Company Info
ATOSSA THERAPEUTICS INC
10202 5Th Avenue Ne, Suite 200
Seattle WASHINGTON 98104 US
CEO: Steven C. Quay
Employees: 13
Phone: 12065880256
ATOSSA THERAPEUTICS INC / ATOS FAQ
What does ATOS do?
Atossa Therapeutics, Inc. operates as a clinical-stage pharmaceutical company, which engages in the development of novel therapeutics and delivery methods for the treatment of breast cancer and other breast conditions. The company is headquartered in Seattle, Washington and currently employs 13 full-time employees. The company went IPO on 2012-11-08. The company is engaged in developing medicines in areas of unmet medical need in oncology with a focus on women’s breast cancer and other breast conditions. Its lead drug candidate under development is oral (Z)-endoxifen, which it is developing for both the prevention and treatment of breast cancer. (Z)-endoxifen is the potent Selective Estrogen Receptor Modulator for estrogen receptor inhibition and causes estrogen receptor degradation. In addition to its potent anti-estrogen effects, (Z)-endoxifen has been shown to target PKCB1, a known oncogenic protein, at clinically attainable blood concentrations. The company is developing a form of (Z)-endoxifen which is administered orally for the potential treatment of breast cancer and reduction of breast density. The company has completed four Phase I clinical studies and two Phase II clinical studies with its proprietary (Z)-endoxifen (including oral and topical formulations).
What is the stock price of ATOSSA THERAPEUTICS INC today?
The current stock price of ATOS is 0.7001 USD. The price decreased by -5.65% in the last trading session.
Does ATOS stock pay dividends?
ATOS does not pay a dividend.
What is the ChartMill rating of ATOSSA THERAPEUTICS INC stock?
ATOS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the market expecting ATOS stock to perform?
10 analysts have analysed ATOS and the average price target is 5.8 USD. This implies a price increase of 728.63% is expected in the next year compared to the current price of 0.7001.
What is the Price/Earnings (PE) ratio of ATOSSA THERAPEUTICS INC (ATOS)?
ATOSSA THERAPEUTICS INC (ATOS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.24).
Can you provide the market cap for ATOSSA THERAPEUTICS INC?
ATOSSA THERAPEUTICS INC (ATOS) has a market capitalization of 90.43M USD. This makes ATOS a Micro Cap stock.
ATOS Technical Analysis
ATOS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to ATOS. No worries on liquidiy or solvency for ATOS as it has an excellent financial health rating, but there are worries on the profitability.
ATOS Financial Highlights
Over the last trailing twelve months ATOS reported a non-GAAP Earnings per Share(EPS) of -0.24. The EPS increased by 4% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -44.51% | ||
| ROE | -49.78% | ||
| Debt/Equity | 0 |
ATOS Forecast & Estimates
10 analysts have analysed ATOS and the average price target is 5.8 USD. This implies a price increase of 728.63% is expected in the next year compared to the current price of 0.7001.